Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Nov 24;101(11):1900–1908. doi: 10.1038/sj.bjc.6605419

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2009 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

p21 induction of cellular senescence induces paclitaxel resistance in HT1080 p21-9 human fibrosarcoma cells. (A) Western blot analysis shows down-regulation of the MAD2 protein following up-regulation of p21, induced by IPTG. GAPDH was used as a loading control. (B) β-galactosidase staining shows an increase in senescent cells following IPTG induction of p21 and concomitant MAD2 down-regulation. (C) The MTT cell viability assay shows the same viability in the HT1080 p21-9 cells before paclitaxel treatment, regardless of p21 induction by IPTG. However, a significant higher viability is displayed by the IPTG-treated cells when compared with the IPTG non-treated cells, after paclitaxel (P<0.001).